Mazdutide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack organizes cited evidence, protocol context, safety cautions, and Australian legal status for the compound.

What the sources say

Mazdutide (IBI362; LY3305677) is a dual GLP-1/glucagon receptor agonist studied in once-weekly subcutaneous trials for weight management and type 2 diabetes, principally in Chinese adults. (Human clinical trials; Ji et al., "Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight", 2025-05-25)
In a 20-week phase 2 type 2 diabetes trial, once-weekly subcutaneous mazdutide reduced HbA1c by 1.41–1.67 percentage points and body weight by up to 7.1%; the study included placebo and dulaglutide comparator arms and some participants on stable metformin. (Human clinical trials; Zhang et al., "Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial", 2023-11-09)
Innovent announced that China's NMPA approved mazdutide for chronic weight management on 2025-06-27; the company's announcement is not evidence of Australian approval. (Manufacturer information; Innovent Biologics, "Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management", 2025-06-27)
The DREAMS-3 registry describes a phase 3 comparison of once-weekly mazdutide with semaglutide in early type 2 diabetes and obesity; the registry record reviewed had no posted results, so it does not establish efficacy or support a combination claim. (Educator material (not peer reviewed); ClinicalTrials.gov, "DREAMS-3: A Multicenter, Randomized, Open-label Phase 3 Study Comparing the Efficacy and Safety of IBI362 Versus Semaglutide in Chinese Participants With Early Type 2 Diabetes and Obesity" (NCT06184568), 2026-06-11)
The obesity and diabetes trials reviewed were conducted mainly in Chinese adults and were relatively short; results do not establish long-term outcomes or identical effects in other populations. (Human clinical trials; Ji et al., "A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity", 2023-12-14)
In the phase 2 type 2 diabetes study, common reported events included diarrhoea (36%), decreased appetite (29%), nausea (23%), vomiting (14%) and hypoglycaemia (10% versus 8% with placebo). These are study-specific event rates. (Human clinical trials; Zhang et al., "Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial", 2023-11-09)
The TGA says unapproved peptide products generally may not have been assessed for quality, safety or effectiveness and may have uncertain composition or sterility; this is a class-level regulatory warning, not a mazdutide-specific adverse-event finding. (Educator material (not peer reviewed); TGA, "How we regulate therapeutic peptide products" (undated page; accessed 2026-10-28), 2026-10-28)
The Chinese NMPA approval announced by Innovent is jurisdiction-specific and does not establish Australian registration or routine supply permission. (Manufacturer information; Innovent Biologics, "Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management", 2025-06-27)
No mazdutide ARTG entry or TGA approval record was identified in the public register search checked on 2026-10-28. This is a search finding, not a published TGA ruling about every possible product or access pathway. (Educator material (not peer reviewed); TGA, "Searching the Australian Register of Therapeutic Goods (ARTG)" (public search checked 2026-10-28; page last updated 2021-06-22), 2026-10-28)
The TGA states that therapeutic peptide products generally need ARTG inclusion before supply in Australia, unless a specific approval, authority or exemption applies; limited unapproved-medicine access pathways do not amount to general marketing approval. (Educator material (not peer reviewed); TGA, "How we regulate therapeutic peptide products" (undated page; accessed 2026-10-28), 2026-10-28)

Sources

Dosing, stacking and protocol details are not published here.